#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Prognostic Significance of the Location of Colorectal Cancer Metastases

An Austrian study presented at the ESMO 2020 conference analyzed the relationship between the localization of colorectal cancer (CRC) metastases and patient survival, the time of metastasis detection, and RAS mutations.
Source: Colorectal Cancer 26. 11. 2021

News New scoring system for predicting long-term survival of AML patients over 70 years and suitable for intensive chemotherapy

Based on the analysis of data from 3 large European registries (DATAML, SAL, and PETHEMA), a prognostic score for 5-year survival was created and validated for patients with acute myeloid leukemia (AML) who were given intensive chemotherapy. The ESS70+ score, determined based on parameters known at the time of diagnosis, is easily usable in routine practice for estimating overall survival of older AML patients and facilitates decisions about intensive chemotherapy.
Source: Acute Myeloid Leukemia 10. 5. 2024

News Possibilities of Using Metamizole in the Treatment of Acute Primary Headaches

The aim of the review article by Brazilian authors was to summarize the efficacy and safety of metamizole in the treatment of acute primary headaches, such as migraine, episodic tension-type headache (ETTH), cluster headache, and unclassified primary pain in adults and children.
Source: Analgesia 26. 10. 2020

News Can tofacitinib have a positive impact on the mental stress of patients with rheumatoid arthritis?

In the population of patients with rheumatoid arthritis (RA), there is a higher incidence of depression and anxiety compared to the healthy population. These psychiatric comorbidities can lead to a reduced quality of life and a poorer response to treatment. The aim of the post-hoc analysis presented below was to monitor the effect of tofacitinib on improving anxiety and depression in patients with RA.
Source: Arthritis 21. 4. 2020

Journal articles Cannabis – therapy for the future?

Author of the article: Jan Hajer Source: Vnitřní lékařství | 7-8/2015 10. 9. 2015

News Current Options and Prospects for Effective Antiemetic Treatment in an Effort to Increase Adherence of Oncological Patients to Chemotherapy

Chemotherapy-induced nausea and vomiting (CINV) is strongly associated with treatment in the minds of many oncology patients, and its occurrence is rated as one of the most dreaded and stressful complications. For most patients, adherence to recommendations for antiemetic prophylaxis can successfully prevent the occurrence of CINV. A review article published last year by an international team of authors in the journal Future Oncology provides an overview of the current spectrum of options in CINV prophylaxis, focusing on the first combined preparation in this indication, containing the active substances netupitant and palonosetron.
Source: Antiemetic Therapy 31. 3. 2020

News Brain Metastases Are Not an Absolute Contraindication for Antiplatelet Therapy

On one hand, there's a higher risk of thromboembolic events, and on the other, a higher risk of intracranial bleeding. Prophylactic and therapeutic interventions for blood clotting are necessary for cancer patients in indicated cases. But what about the risk of bleeding in patients with CNS malignancies?
Source: Genetic Profile and Treatment of NSCLC 27. 12. 2021

News The Future and Prospects of Type 2 Diabetes Therapy: Can We Fully Cure It with Endoscopy or Genetics?

Diabetes mellitus (DM) cannot be cured, but it can be successfully treated... Will we rewrite this textbook fact passed down for years in the future? Will we be able to completely cure type 2 diabetes mellitus (T2DM) one day? The Prague Institute for Clinical and Experimental Medicine (IKEM) sees endoscopic procedures as one of the promising paths and is preparing to test this groundbreaking method of therapy.
Source: Modern Treatment of Diabetes 6. 5. 2021

News Principle of Slowed Wound Healing Due to Stress Revealed

There is no doubt that psychological stress significantly slows down the process of healing wounds. The principle of how this phenomenon occurs, however, has remained unexplained. Swiss scientists focused on macrophages. Their function is to remove pathogens from the healing wound.
Source: Wound Healing 28. 4. 2020

News Lung Recovery After COVID-19: How Reversible is the Damage?

During the virtual XXV Hradec Pulmonology Days held in April 2021, various aspects concerning COVID-19 were among the major topics. Dr. Bram van den Borst from Radboud University Nijmegen provided a comprehensive summary of current insights regarding lung recovery following an infection.
Source: COPD 22. 6. 2021

News How does the level of uric acid affect the incidence of cardiorenal events in patients with T2DM and CVD?

One of the post hoc analyses of the well-known EMPA-REG OUTCOME study provided data on the relationship between uric acid levels and the incidence of cardiorenal events in type 2 diabetics with existing cardiovascular disease.
Source: Diabetes 21. 7. 2023

News Can Empagliflozin Also Act Against Gout?

Gliflozins, or sodium-glucose cotransporter 2 inhibitors (SGLT2i), are not only effective antidiabetic agents but also exhibit cardio- and renoprotective effects. It now appears that in type 2 diabetics, they may lower serum uric acid levels and help prevent the development of gout. This was suggested by a post hoc analysis of data from the EMPA-REG OUTCOME study in the case of empagliflozin.
Source: Diabetes 21. 7. 2023

News Can SGLT2 Inhibition Also Reduce the Risk of Nephrolithiasis?

Diabetes mellitus (DM) is a risk factor for the development of nephrolithiasis. Recent studies associated with nephrolithiasis suggest a possible beneficial effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i, also known as gliflozins), a significant group of modern antidiabetics. Below we summarize findings from a study that explored this potential in empagliflozin using conducted phase I–IV studies, including EMPA-REG OUTCOME.
Source: Diabetes 21. 8. 2023

News How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?

Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2 diabetes mellitus (DM2), examining the cardiovascular risk impact when treated with empagliflozin, liraglutide, or sitagliptin. Currently, there is limited evidence comparing the effectiveness of various glucose-lowering agents intended for second-line treatment in DM2 patients undergoing routine care, who have a broad spectrum of cardiorenal risks.
Source: Diabetes 28. 8. 2023

News Is it possible to extend the life of diabetics thanks to modern treatment?

People aged 60 with type 2 diabetes are estimated to live on average 6-7 years less compared to their peers without a diabetes diagnosis. However, clinical study results suggest that modern therapy can prevent these lost years.
Source: Diabetes 29. 4. 2022

News Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin

Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.
Source: Diabetes 19. 4. 2022

News Albuminuria as a Risk Factor for Cardiovascular Events and Mortality in Patients with Type 2 Diabetes Without Apparent Cardiovascular Disease

Albuminuria in patients with type 2 diabetes is associated with a higher risk of cardiovascular (CV) events and higher mortality. However, this association has not been thoroughly investigated in diabetics without evident atherosclerotic disease. A study with a large cohort of Danish patients helped fill in the missing data.
Source: Diabetes 12. 4. 2022

News Gut-Brain Axis − Future of MS Treatment?

The relationship between the gut microbiome and multiple sclerosis has been a major topic recently. How far has current science progressed in decoding this issue? A recent review article published in the journal Neuroscience Research summarizes the existing findings on the relationship of the gut microbiome to the etiopathogenesis and course of multiple sclerosis (MS).
Source: Multiple Sclerosis 3. 5. 2022

News Comparison of Pharmacological Properties of Micronized Diosmin and Hesperidin in the Treatment of Chronic Venous Insufficiency and Hemorrhoids

Diosmin and hesperidin belong to the group of bioflavonoids, which currently find wide application in the treatment of chronic venous insufficiency and hemorrhoidal disease. Both flavonoids have been described to have a similar, but still not fully understood mechanism of action. Nevertheless, diosmin significantly differs from hesperidin, especially in pharmacokinetic parameters, which makes it the main carrier of the effect of venotonics.
Source: Venous Insufficiency 6. 10. 2020

Journal articles Iron metabolism and its regulations

Author of the article: D. Vyoral, J. Petrák Source: Vnitřní lékařství | Suppl 2/2012 17. 8. 2012

News Targeted Treatment of Children and Adolescents with Severe AD – Case Studies

The results of therapy with dupilumab in children and adolescents with severe forms of atopic dermatitis (AD) are very good even after a short period, not only from a health perspective but also in terms of the social aspect of the disease and the quality of life of patients. This is illustrated by the following two case studies – an 8-year-old girl and a 17-year-old boy – from the Center for Biological Treatment at the Dermatovenerology Clinic of the 2nd Faculty of Medicine, Charles University, and Bulovka University Hospital.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 2. 3. 2023

News Micronutrients in Parenteral Nutrition in Adult Patients – Current Issues and Consensus

Micronutrients are a key nutritional component, and this is also true for patients whose condition requires the administration of parenteral nutrition. An article published last year in the Journal of Parenteral and Enteral Nutrition summarizes the expert literature on this topic as well as current guidelines and addresses 14 clinically most relevant questions related to the importance, administration, and monitoring of micronutrients.
Source: Parenteral Nutrition 23. 11. 2020

News Preserving Quality of Life for Patients During Palliative Treatment of Triple-Negative Breast Cancer

An analysis of the quality of life of patients treated with a combination of atezolizumab with nab-paclitaxel for metastatic triple-negative breast cancer was published in the Annals of Oncology journal.
Source: Breast Carcinoma 28. 5. 2020

News CASE STUDY: Key Benefits of GLP-1RA in Diabetes Therapy in the Office of a General Practitioner

Modern therapy using glucagon-like peptide-1 receptor agonists (GLP-1RA) offers diabetics highly effective management of their primary condition as well as several other advantages: it reduces the risk of hypoglycemia, aids in weight loss, and has a positive impact on the heart and blood vessels, including increasing the chances of preventing and delaying the progression of micro and macrovascular complications. Early initiation of this treatment not only significantly improves diabetes control but also helps in preventing or delaying the development of atherosclerosis and cardiometabolic syndrome.
Source: Modern Treatment of Diabetes with GLP-1 Analogues 16. 5. 2024

News Low Molecular Weight Heparin in an ECMO Patient − Case Study

Extracorporeal membrane oxygenation (ECMO) has an irreplaceable role in intensive care medicine. In the context of preventing complications caused by blood clot formation, unfractionated heparin is most commonly used in patients on extracorporeal circulation. However, its administration can lead to complex coagulopathies, which may result in increased bleeding or, perhaps surprisingly, a higher frequency of blood clot formation. A unique case study recently presented by authors from Motol University Hospital in Prague demonstrates the safety and effectiveness of using low molecular weight heparin (LMWH) enoxaparin in this indication for a patient connected to ECMO for a very long duration (3 months), with several days even on two devices simultaneously.
Source: Thromboprophylaxis 28. 11. 2023

1 32 33 34 35 36 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#